CEO and Co-Founder
at Pixelgen Technologies
Dr. Simon Fredriksson is continually fascinated by technological innovation that pushes the frontiers of scientific discovery into new and uncharted territories. His deep experience as a life science entrepreneur, researcher, and inventor has spanned from genomics to proteomics research tools. Fredriksson was co-founder, chief science officer, and CEO of Olink AB, which later became Olink Proteomics AB, now part of Thermo Fisher. He led the development and commercialization of multiple product lines, most notably the Proximity-Extension Assays (PEA) platform for high throughput multiplex protein detection. He served on the boards of Moligo Technologies, Olink AB, Olink Proteomics AB, Biolamina AB, Basic Genomics AB, and Cartana AB. Fredriksson earned his doctorate in molecular medicine from Uppsala University and spent four years in research at Stanford University. He is an inventor with several patents and patent applications on Proximity Ligation and Proximity Extension. He developed Proximity-Ligation Assay (PLA) technology during his graduate work and further expanded the technology into a multiplexed protein detection tool for biomarker research. These assay concepts of PEA and PLA are now in use by Olink, Alamar, SpearBio, and others for plasma proteomics. Fredriksson is co-founder of Pixelgen Technologies, pioneering protein interactomics at scale with the Proximity Network Assay. He is formerly adjunct professor of engineering in molecular diagnostics at the Royal Institute of Technology (KTH).
Education
Awards & Certifications
Finalist in the European Patent Office, inventor of the year 2024, for his work on the Olink patents
Areas of Expertise
Got a Question for Simon Fredriksson, PhD?
Get in touch using the contact form linked here and we'll get back to you shortly.